Company Profile
Moleculin Biotech, Inc. Stock Price, News & Analysis
- Ticker:
- MBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.39 USD (-1.28%)
Close
Last updated: August 6, 2026
13.1M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MBRX closed down 1.28% at $0.3850. No new same-company headline was identified in the current news window.
Company overview
Late-Stage Oncology Developer
Moleculin Biotech develops therapies for difficult-to-treat cancers and viral diseases. Its lead program, Annamycin/naxtarubicin, is an anthracycline designed to avoid multidrug-resistance mechanisms and reduce the cardiotoxicity associated with conventional anthracyclines.
Differentiated Anthracycline Design
Annamycin is intended to retain antitumor activity in settings where resistance limits conventional anthracyclines. Its development strategy combines this differentiated drug profile with cytarabine in AML and explores additional applications in metastatic solid tumors.
Annamycin and AnnAraC
The pivotal MIRACLE study is evaluating Annamycin in combination with cytarabine, known as AnnAraC, in relapsed or refractory acute myeloid leukemia. An interim analysis of the first 45 patients in Part A showed higher complete response and composite complete response rates in both Annamycin dose groups than in the HiDAC control arm.
Soft Tissue Sarcoma Program
Annamycin is also being developed for lung metastases from soft tissue sarcoma. This program tests whether the asset’s anthracycline profile can provide activity in a solid-tumor setting with substantial prior treatment exposure.
Earlier-Stage Pipeline
Additional programs include WP1066 and WP1122 for brain tumors, pancreatic cancer, other malignancies, and potential viral indications. These assets provide pipeline breadth beyond the company’s lead Annamycin franchise.
Future catalysts
Enrollment will continue in Part A of the pivotal Phase 2/3 MIRACLE trial toward its target of 90 patients, supporting selection of the optimal Annamycin dose.
Planned follow-up analyses from MIRACLE will inform the registrational path and future FDA interactions for AnnAraC in relapsed or refractory AML.
Recent news
- 01
Moleculin Announces Pricing of $9.3 Million Public Offering
Source: Moleculin Biotech, Inc.
- 02
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Source: Moleculin Biotech, Inc.
- 03
- 04
- 05
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Source: Moleculin Biotech, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Moleculin Biotech, Inc. (MBRX)?
Moleculin Biotech, Inc. (MBRX) most recently closed at 0.39 USD, a -1.28% move versus the previous session.
What is the market cap of Moleculin Biotech, Inc. (MBRX)?
Moleculin Biotech, Inc. currently has a market capitalization of 13.1M USD on BioPharmSignal.
What does Moleculin Biotech, Inc. do?
Late-Stage Oncology Developer Moleculin Biotech develops therapies for difficult-to-treat cancers and viral diseases. Its lead program, Annamycin/naxtarubicin, is an anthracycline designed to avoid multidrug-resistance mechanisms and reduce the cardiotoxicity associated with conventional anthracyclines. Differentiated Anthracycline Design Annamycin is...
On which exchange is MBRX stock listed?
Moleculin Biotech, Inc. (MBRX) is associated with NASDAQ, United States, Biopharma.
What is Late-Stage?
Late-Stage Oncology Developer Moleculin Biotech develops therapies for difficult-to-treat cancers and viral diseases.
Which conditions is Moleculin Biotech, Inc. targeting with Late-Stage?
Moleculin Biotech, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Moleculin Biotech, Inc. describe recent progress with Late-Stage?
Enrollment will continue in Part A of the pivotal Phase 2/3 MIRACLE trial toward its target of 90 patients, supporting selection of the optimal Annamycin dose. Planned follow-up analyses from MIRACLE will inform the registrational path and future FDA interactions for AnnAraC in relapsed or refractory AML.
What is Oncology?
Late-Stage Oncology Developer Moleculin Biotech develops therapies for difficult-to-treat cancers and viral diseases.